Evidence map›Paper›PMID 40335778›Full record

ReviewJournal of neurology2025

Novel strategies for targeting tau oligomers in neurodegenerative diseases.

Jing Lin, Hong Li, Lingxia Jiang, Jian Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jing LinDepartment of Blood Transfusion, The Third Xiangya Hospital of Central South University, Tongzipo Road, Changsha, 410000, Hunan, China.ORCID http://orcid.org/0009-0003-7546-1557
Hong LiDepartment of Blood Transfusion, The Third Xiangya Hospital of Central South University, Tongzipo Road, Changsha, 410000, Hunan, China.
Lingxia JiangDepartment of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Tongzipo Road, Changsha, 410000, Hunan, China.
Jian LiDepartment of Blood Transfusion, The Third Xiangya Hospital of Central South University, Tongzipo Road, Changsha, 410000, Hunan, China. 603196@csu.edu.cn.ORCID http://orcid.org/0000-0001-6562-6483

Funding

Health Research Project of Hunan Provincial Health Commission Grant No.W20243174the Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University Grant No.YX202206
6 · The paper itself

Abstract

Tau protein is a soluble microtubule-associated protein enriched in neurons, is mainly distributed in the central nervous system, and is responsible for stabilizing neurons. Tau maintains nerve cell morphology and internal transport by binding to normal microtubules. In neurodegenerative diseases, such as Alzheimer's disease (AD), tau proteins undergo aberrant phosphorylation, resulting in their removal from microtubules and the formation of neurofibrillary tangles (NFTs), which are key pathological features. In contrast to the late formation of non-soluble NFTs, early, smaller, soluble tau oligomers (tauO) with disseminated toxicity are considered necessary in neurodegenerative disorders, such as the primary form of tau toxicity in the AD process. Although an increasing number of studies are focusing on tauO, there are still problems to be solved, mainly concerning the molecular and inhibitory mechanisms of tauO toxicity. In this paper, we summarize the new strategies for the molecular mechanisms of tauO toxicity, detection methods, and interventions in the last five years. An outlook on these new strategies and the challenges that may be foreseen is presented to provide new directions for future applications in the clinical treatment of neurodegenerative diseases.

Indexed as

Neurodegenerative Diseasestau ProteinsAnimalsHumansNeurofibrillary Tanglestau ProteinsAlzheimer's diseaseNeurodegenerative diseasesTauTau oligomers

Identifiers

PMID40335778

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.